Beam Therapeutics shared early Phase 1/2 data for a base editing therapy targeting glycogen storage disease type Ia (GSD Ia), marking the company’s first disclosed results for the program. The update centers on demonstrating on-target genome editing with an emphasis on local delivery and acceptable safety. Beam’s approach continues the field’s pivot toward precise nucleotide changes—especially where endogenous enzyme deficits are well-characterized—and away from older gene addition strategies when genotype–phenotype mapping can guide editing design. For investors and trialists, the immediate question is whether first-in-human signals translate into measurable pharmacodynamic improvement in relevant tissues, while maintaining the safety profile expected for permanent genome edits.